Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)

Cabio Biotech (Wuhan) Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	192.52	153.15	239.68	494.33	664.47	847.32
Trading Asset Securities	65.7	0.03	0.03	32.8	11.5	13.52
Cash & Short-Term Investments	258.22	153.18	239.71	527.13	675.97	860.84
Cash Growth	62.78%	-36.10%	-54.53%	-22.02%	-21.48%	1.96%
Accounts Receivable	243.83	285.41	265.64	216.43	178.29	139.29
Other Receivables	20.03	36.39	31.01	40.56	41.08	36.65
Receivables	263.86	321.81	296.65	256.99	219.37	175.94
Inventory	177.54	139.32	112.58	81.49	74.86	65.48
Other Current Assets	57.48	42.36	59.84	41.76	24.66	20.89
Total Current Assets	757.1	656.67	708.78	907.37	994.85	1,123
Property, Plant & Equipment	838.36	767.92	643.28	485.96	241.93	149.51
Long-Term Investments	166.96	191.84	175.37	150.22	117.31	65.93
Other Intangible Assets	41.88	43.09	41.08	36.34	13.15	14.54
Long-Term Deferred Tax Assets	7.98	9.36	11.13	11.49	5.98	6.12
Long-Term Deferred Charges	0.73	1.86	3.67	2.45	0.38	-
Other Long-Term Assets	9.78	16.07	28.18	17.52	74.89	23.59
Total Assets	1,823	1,687	1,611	1,611	1,448	1,383
Accounts Payable	44.83	62.07	70.86	107.34	31.43	24.53
Accrued Expenses	14.35	21.97	15.32	19.15	18.05	17.51
Short-Term Debt	56.77	6.01	11.01	30.03	-	-
Current Portion of Leases	0.19	0.64	1.09	1.35	0.84	-
Current Income Taxes Payable	5.64	5.18	5.86	16.02	5.22	3.59
Current Unearned Revenue	1.03	0.76	2.08	0.43	0.23	2.89
Other Current Liabilities	7.85	5.17	6.2	6.12	4.18	3.79
Total Current Liabilities	130.66	101.79	112.42	180.44	59.95	52.32
Long-Term Debt	47.71	12.63	-	-	-	-
Long-Term Leases	-	0.02	0.66	1.66	1.58	-
Long-Term Unearned Revenue	4.99	2.73	4.2	3.66	4.92	6.45
Long-Term Deferred Tax Liabilities	0.07	0.11	0.31	0.54	0.22	0.53
Total Liabilities	183.42	117.27	117.6	186.31	66.68	59.3
Common Stock	168.31	168.31	168.31	120	120	120
Additional Paid-In Capital	811.83	811.83	811.83	858.02	844.82	870.72
Retained Earnings	683.19	587.5	496.95	441.64	416.9	327.92
Treasury Stock	-34.79	-10.82	-	-	-	-
Comprehensive Income & Other	-0.74	-0.74	-0.74	-0.73	-0.69	-0.7
Total Common Equity	1,628	1,556	1,476	1,419	1,381	1,318
Minority Interest	11.59	13.46	17.54	6.1	0.79	5.59
Shareholders' Equity	1,639	1,570	1,494	1,425	1,382	1,324
Total Liabilities & Equity	1,823	1,687	1,611	1,611	1,448	1,383
Total Debt	104.66	19.29	12.76	33.05	2.42	-
Net Cash (Debt)	153.56	133.89	226.95	494.08	673.55	860.84
Net Cash Growth	9.41%	-41.01%	-54.07%	-26.65%	-21.76%	1.96%
Net Cash Per Share	0.91	0.80	1.34	2.92	4.00	5.13
Filing Date Shares Outstanding	166.8	167.75	168.31	168	168	168
Total Common Shares Outstanding	166.8	167.75	168.31	168	168	168
Working Capital	626.44	554.88	596.35	726.92	934.9	1,071
Book Value Per Share	9.76	9.28	8.77	8.45	8.22	7.84
Tangible Book Value	1,586	1,513	1,435	1,383	1,368	1,303
Tangible Book Value Per Share	9.51	9.02	8.53	8.23	8.14	7.76
Buildings	-	241.94	241.02	191	94.66	98.57
Machinery	-	636	594.21	529.66	312.24	306.14
Construction In Progress	-	265.55	133.05	49.59	104.18	1.25

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.